Non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of 25% and is a leading cause of cirrhosis and hepatocellular carcinoma. NAFLD encompasses a disease continuum from steatosis with or without mild inflammation (non-alcoholic fatty liver), to non-alcoholic steatohepatitis (NASH), whic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet (British edition) Jg. 397; H. 10290; S. 2212 - 2224
Hauptverfasser: Powell, Elizabeth E, Wong, Vincent Wai-Sun, Rinella, Mary
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England Elsevier Ltd 05.06.2021
Elsevier B.V
Elsevier Limited
Schlagworte:
Australia
Biopsy
Carcinoma, Hepatocellular - pathology
Cardiovascular diseases
Cirrhosis
Developmental stages
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - complications
Disease Progression
Drug approval
Drug development
Epidemiology
Esophagus
Fatty liver
Fibrosis
Gastrointestinal diseases
Health aspects
Health services
Hepatitis
Hepatocellular carcinoma
Heterogeneity
Humans
Hypertension
Inflammation
Liver
Liver cancer
Liver cirrhosis
Liver Cirrhosis - pathology
Liver diseases
Liver Neoplasms - pathology
Malignancy
Medical colleges
Medical research
Medicine, Experimental
Metabolic disorders
Metabolic syndrome
Mortality
Natural history
Non-alcoholic Fatty Liver Disease - epidemiology
Non-alcoholic Fatty Liver Disease - pathology
Non-alcoholic Fatty Liver Disease - physiopathology
Obesity
Phenotypes
Population
Research institutes
Risk factors
Steatosis
Transplants & implants
Type 2 diabetes
Weight reduction
Australia
United States > US
ISSN:0140-6736, 1474-547X, 1474-547X
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of 25% and is a leading cause of cirrhosis and hepatocellular carcinoma. NAFLD encompasses a disease continuum from steatosis with or without mild inflammation (non-alcoholic fatty liver), to non-alcoholic steatohepatitis (NASH), which is characterised by necroinflammation and faster fibrosis progression than non-alcoholic fatty liver. NAFLD has a bidirectional association with components of the metabolic syndrome, and type 2 diabetes increases the risk of cirrhosis and related complications. Although the leading causes of death in people with NAFLD are cardiovascular disease and extrahepatic malignancy, advanced liver fibrosis is a key prognostic marker for liver-related outcomes and overall mortality, and can be assessed with combinations of non-invasive tests. Patients with cirrhosis should be screened for hepatocellular carcinoma and oesophageal varices. There is currently no approved therapy for NAFLD, although several drugs are in advanced stages of development. Because of the complex pathophysiology and substantial heterogeneity of disease phenotypes, combination treatment is likely to be required for many patients with NAFLD. Healthy lifestyle and weight reduction remain crucial to the prevention and treatment of NAFLD.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0140-6736
1474-547X
1474-547X
DOI:10.1016/S0140-6736(20)32511-3